ClinicalTrials.gg
Sign In
CompletedNCT03313583PopReceveurUpdated Oct 18, 2017

French One Day Survey in 2011 - Knowing Our Population of Labile Blood Products Recipients

An observational study in Blood Product Transfusion for All Conditions, Trauma and Surgical Blood Loss, sponsored by Etablissement Français du Sang. Completed. Per ClinicalTrials.gov, last updated 2017-10-18.

Sponsored by Etablissement Français du Sang · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
4,720
Sex
All
01

Study summary

Describe the epidemiologic profile and clinical context of transfusion recipients in France. Describe the clinical context of transfusion.

Describe the characteristics of the transfusion prescriptions, the use of blood products and the main indications for transfusion.

Describe transfusion practice according the type of hospital stay.

02

Conditions studied

  • Blood Product Transfusion for All Conditions
  • Trauma
  • Surgical Blood Loss
  • Hematologic Diseases
03

In context

Wounds and Injuries

2,217 studies on the registry are indexed under Wounds and Injuries; 440 are open to participants now.

This study's enrollment of 4,720 is above the median of 169 across 690 observational studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Etablissement Français du Sang is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

french population of recipients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Transfusion with at least one blood product on the day of the study.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
4,720 participants (actual)
Patient registry
No

Groups and cohorts

  • Blood product recipients

    All patients who received at least one blood product on the day of the study

    Procedure: Transfusion of blood products

Interventions

  • ProcedureTransfusion of blood products
06

What researchers measure

Primary outcomes

  1. Number of red blood cell concentrates received

    transversal study

    Time frame: 1 day (cross sectional)

  2. Number of platelet concentrates recevied

    transversal study

    Time frame: 1 day (cross sectional)

  3. Number of plasma units received

    transversal study

    Time frame: 1 day (cross sectional)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Fillet AM, Desmarets M, Assari S, Quaranta JF, Francois A, Pugin A, Schuhmacher A, Lassale B, Monnet E, Cabre P, Legrand D, Binda D, Djoudi R. Blood products use in France: a nationwide cross-sectional survey. Transfusion. 2016 Dec;56(12):3033-3041. doi: 10.1111/trf.13887. Epub 2016 Nov 2. PubMed 27807857 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2011 to primary completion in Nov 2011, 0 months.

Of 265 non-industry observational studies under Wounds and Injuries, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 60. This study's 0 months is below that.

Counting every sponsor, half of 312 studies reached it within 28 months; a quarter within 12 and three quarters within 60.

Wounds and Injuries covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2017
First posted
Oct 18, 2017
StartActual
Nov 1, 2011
Primary completionActual
Nov 1, 2011
CompletionActual
Dec 1, 2011
Last update
Oct 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03313583
Lead sponsor
Etablissement Français du Sang
Collaborators
Centre Hospitalier Universitaire de Besancon, Centre Hospitalier Universitaire de Nice, Assistance Publique Hopitaux De Marseille, Région Nord-Pas de Calais, France
Responsible party
Sponsor
First posted
Oct 18, 2017
Start date
Nov 1, 2011
Primary completion
Nov 1, 2011
Completion
Dec 1, 2011
Last update
Oct 18, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Wounds and Injuries →

Other studies from this sponsor

Etablissement Français du Sang

Start the discussion